Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(6): 331-333
DOI: 10.1055/s-2005-837666
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Ovarian Function after Radioiodine Therapy in Patients with Thyroid Cancer

P. W. Souza Rosário1 , T. Alvarenga Fagundes1 , A. S. Villas-Boas Fagundes1 , Á. L. Barroso1 , L. Lamego Rezende1 , E. Lanza Padrão1 , V. C. Guimarães1 , A. C. Horta1 , M. Franco1 , S. Purisch1
  • 1Nuclear Medicine and Endocrinology Service, Santa Casa de Belo Horizonte, Minas Gerais, Brazil
Further Information

Publication History

Received: June 16, 2004 First decision: July 14, 2004

Accepted: January 21, 2005

Publication Date:
23 June 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: To assess ovarian function in young women treated with radioiodine. Methods: The study was conducted on 50 women with thyroid carcinoma aged less than 40 years (mean, 29.8 years), with regular menstrual cycles and normal FSH levels prior to radioiodine therapy. FSH determination was repeated 6 and 12 months after radioiodine therapy (mean, 4.24 GBq iodine-131) and menstrual cycles were monitored during this period. Results: Twenty percent of the patients reported amenorrhea during the first year. FSH levels increased after 6 months (from 5.1 ± 1.8 to 10.6 ± 2.2 IU/l, p < 0.00 001) and 28 % of the patients showed elevated values, which had returned to normal by the end of the first year. Conclusion: Radioiodine causes transitory alterations in ovarian function even in younger women and after a mean activity of 4.2 GBq (115 mCi).

Key words

Ovarian function - radioiodine - thyroid cancer

References

  • 1 Bushberg J T, Seibert J A, Leidholdt Jr E M, Boone J M. The Essential Physics of Medical Imaging. Baltimore; William & Wilkins 1994: 673
    Search in Google Scholar
  • 2 Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.  J Clin Endocrinol Metab. 2001;  86 3512-3515
    CrossrefPubMedSearch in Google Scholar
  • 3 Izembart M, Chauvadra J, Aubert B, Vallèe G. Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer.  Eur J Nucl Med. 1992;  19 243-247
    PubMedSearch in Google Scholar
  • 4 Maxon III H R. The role of I-131 in the treatment of thyroid cancer.  Thyroid Today. 1993;  16 1-9
    PubMedSearch in Google Scholar
  • 5 Raymond J P, Izembart M, Marliac V, Dagousset F, Merceron R E, Vulpillat M, Vallée G. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine.  J Clin Endocrinol Metab. 1989;  69 186-190
    PubMedSearch in Google Scholar
  • 6 Schlumberger M J. Medical progress-papillary and follicular thyroid carcinoma.  N Engl J Med. 1998;  338 297-306
    CrossrefPubMedSearch in Google Scholar
  • 7 Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognostic for fertility and ovarian function after treatment with radioiodine for thyroid cancer.  Postgrad Med J. 2002;  78 92-93
    CrossrefPubMedSearch in Google Scholar

Pedro Weslley Souza Rosário

Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia (CEPCEM)

Av Francisco Sales, 1111, 5 andar Ala D

Santa Efigênia, CEP 30150-221, Belo Horizonte, MG

Brasil

Phone: + 3132130836

Fax: + 31 32 13 08 36

Email: pedrorosario@globo.com.br